ACTIVE

EPICS THERAPEUTICS

Export PDF

Financial year 2025 · Closed on 31/12/2025

Net result-5,8 M €-19,7 %over 1 year

Gross margin4,2 M €+4,8 %over 1 year

Equity9,1 M €+15,3 %over 1 year

Workforce32,2 ETP+1,6 %over 1 year

Identity

Source · BCE/KBO

EPICS THERAPEUTICS is a Public limited company incorporated in 2018. Its main activity is: Manufacture of pharmaceutical preparations. Its registered office is in Charleroi. It employs on average 32,2 ETP workers (FTE).

Legal situation: Normal situation
BCE/KBO no. / VAT: BE 0690.759.071
Incorporation: 20/02/2018
Legal form: Public limited company
Registered office: Rue Adrienne Bolland 47
6041 Charleroi · WallonieSee on map
Contributed capital: 19 746 471,57 €
Latest accounts: 31/12/2025
Average workforce: 32,2 ETP

Activities (NACE)

21201Manufacture of pharmaceutical preparations· main 21201Manufacture of pharmaceutical preparations 72101Research and experimental development on natural sciences and engineering 72110Research and experimental development on biotechnology 72101Research and experimental development on natural sciences and engineering 72110Research and experimental development on biotechnology

Joint committees (1)

Signals

Solid equityLow riskGood liquidityPositive cashflowPositive EBITDAHealthy social debts

Financials

Source · NBB, 10 filings

Trend over 7 financial years

	2025		2024		2023		2022		2021
Income statement
Gross margin	4,2 M €	+4.8%	4 M €	+20.3%	3,4 M €	-26.9%	4,6 M €	+16.5%	3,9 M €
EBITDA	925,7 k €	+10.7%	836,1 k €	+112%	394,3 k €	-76.2%	1,7 M €	+23.9%	1,3 M €
Operating result	-5,5 M €	-12.0%	-4,9 M €	+25.4%	-6,6 M €	-16.9%	-5,6 M €	-11.1%	-5,1 M €
Net result	-5,8 M €	-19.7%	-4,8 M €	+22.6%	-6,3 M €	-15.9%	-5,4 M €	-16.6%	-4,6 M €
Balance sheet
Equity	9,1 M €	+15.3%	7,9 M €	+2.1%	7,7 M €	-44.7%	14 M €	+41.3%	9,9 M €
Total assets	14,7 M €	+6.4%	13,8 M €	+48.3%	9,3 M €	-41.8%	16 M €	+41.1%	11,3 M €
Cash	9,2 M €	+4.7%	8,8 M €	+111%	4,2 M €	-65.8%	12,2 M €	+56.0%	7,8 M €
Debts	5,6 M €	+2.1%	5,5 M €	+294%	1,4 M €	-19.9%	1,7 M €	+23.0%	1,4 M €
Other
Workforce	32,2 ETP	+1.6%	31,7 ETP	-2.2%	32,4 ETP	+1.2%	32,0 ETP	+4.6%	30,6 ETP

Valuation

Indicative valuation

As an indication, this company is worth

between 10 M€ and 25 M€

See the valuation

Board of directors

Source · NBB, accounts to 31/12/2025

8 active · 8 ended

Active mandates

Director	Mandates in this company	Period	Other mandatescurrentendedstruck offbankruptcies
EJM ConsultingRepresented by Elisabeth Svanberg	Director20/09/2022 → 14/05/2030
JCO Consulting0693.684.414Represented by Jean Combalbert	Director07/05/2025 → 14/05/2030
JUNOMATI0720.645.365Represented by Bart De Leeuw	Director28/06/2024 → 14/05/2030
Newton Biocapital Partners0673.852.565Represented by Alain Parthoens	Director11/05/2023 → 14/05/2030
SOCIETE FEDERALE DE PARTICIPATIONS ET D'INVESTISSEMENT0253.445.063Represented by Francois Fontaine	Director28/06/2024 → 14/05/2030
SPARAXIS0452.116.307Represented by Caroline Thielen	Director28/02/2018 → 14/05/2030
Graeme Fraser	Managing director11/09/2024 → 14/05/2030
GEMA0841.256.551Represented by Michel Allé	Chairman of the board of directors04/02/2019 → 13/05/2025

Ended mandates

Director	Mandates in this company	Period	Other mandatescurrentendedstruck offbankruptcies
Elisabeth Svanberg	Director20/09/2022 → 2023 accounts
Franz Obermayr	Managing director31/01/2022 → 2023 accounts
Eric Paul Pâques	Director11/05/2021 → 2021 accounts
A Q INVEST0892.924.986Represented by Alain Parthoens	Director04/02/2019 → 2021 accounts

Other companies at this address

Rue Adrienne Bolland 47 6041 Charleroi

Company	CBE no.
LOVAT FRASER CONSULTING● Active	0715.992.731

Full financial information

Source · NBB

	2025	2024	2023	2022	2021	2020
Type of account	Abridged model	Abridged model	Abridged model	Abridged model	Abridged model	Abridged model
Start of the financial year	01/01/2025	01/01/2024	01/01/2023	01/01/2022	01/01/2021	01/01/2020
Closing of the financial year	31/12/2025	31/12/2024	31/12/2023	31/12/2022	31/12/2021	31/12/2020
Length of the financial year	12 months	12 months	12 months	12 months	12 months	12 months
Filing date	23/06/2026	24/11/2025	09/07/2024	17/08/2023	01/09/2022	11/06/2021
General meeting	12/05/2026	08/05/2025	14/05/2024	11/05/2023	12/05/2022	11/05/2021
Currency of the financial year	EUR	EUR	EUR	EUR	EUR	EUR
NBB quality label	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls

Financial ratios

Source · NBB

Looking for more information about this company?

Try for free

Annual accounts filings

Source · NBB, 10 filings

Model	Closing	General meeting	Filed	Language	Document
Abridged model	31/12/2025	12/05/2026	23/06/2026	French	PDF
Abridged modelCorrection	31/12/2024	08/05/2025	24/11/2025	French	PDF
Abridged modelCorrection	31/12/2024	08/05/2025	21/11/2025	French	PDF
Abridged model	31/12/2024	08/05/2025	13/10/2025	French	PDF
Abridged model	31/12/2023	14/05/2024	09/07/2024	French	PDF
Abridged model	31/12/2022	11/05/2023	17/08/2023	French	PDF
Abridged model	31/12/2021	12/05/2022	01/09/2022	French	PDF
Abridged model	31/12/2020	11/05/2021	11/06/2021	French	PDF
Abridged model	31/12/2019	12/05/2020	24/06/2020	French	PDF
Abridged model	31/12/2018	14/05/2019	24/05/2019	French	PDF

Indicative valuation

Order of magnitude

As an indication, this company is worth

between 10 M€ and 25 M€

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan

Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Board of directors

Source · NBB, accounts to 31/12/2025

8 active · 8 ended

Active mandates

Director	Mandates in this company	Period	Other mandatescurrentendedstruck offbankruptcies
EJM ConsultingRepresented by Elisabeth Svanberg	Director20/09/2022 → 14/05/2030
JCO Consulting0693.684.414Represented by Jean Combalbert	Director07/05/2025 → 14/05/2030
JUNOMATI0720.645.365Represented by Bart De Leeuw	Director28/06/2024 → 14/05/2030
Newton Biocapital Partners0673.852.565Represented by Alain Parthoens	Director11/05/2023 → 14/05/2030
SOCIETE FEDERALE DE PARTICIPATIONS ET D'INVESTISSEMENT0253.445.063Represented by Francois Fontaine	Director28/06/2024 → 14/05/2030
SPARAXIS0452.116.307Represented by Caroline Thielen	Director28/02/2018 → 14/05/2030
Graeme Fraser	Managing director11/09/2024 → 14/05/2030
GEMA0841.256.551Represented by Michel Allé	Chairman of the board of directors04/02/2019 → 13/05/2025

Ended mandates

Director	Mandates in this company	Period	Other mandatescurrentendedstruck offbankruptcies
Elisabeth Svanberg	Director20/09/2022 → 2023 accounts
Franz Obermayr	Managing director31/01/2022 → 2023 accounts
Eric Paul Pâques	Director11/05/2021 → 2021 accounts
A Q INVEST0892.924.986Represented by Alain Parthoens	Director04/02/2019 → 2021 accounts

Ownership and network

Looking for more information about this company?

Try for free

Belgian Official Gazette publications

Source · Belgian Official Gazette

Capital / shares04/08/2026
CAPITAL, ACTIONS
PDF
Capital / shares07/04/2026
CAPITAL, ACTIONS
PDF
Mandates03/07/2025
STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS, ) - CAPITAL, ACTIONS - DEMISSIONS, NOMINATIONS
PDF
Other30/04/2025
DIVERS
PDF
Mandates13/11/2024
DEMISSIONS, NOMINATIONS
PDF
Mandates14/08/2024
STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS, ) - CAPITAL, ACTIONS - DEMISSIONS, NOMINATIONS
PDF
Mandates16/07/2024
CAPITAL, ACTIONS - DEMISSIONS, NOMINATIONS
PDF
Mandates22/05/2023
DEMISSIONS, NOMINATIONS
PDF

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

Timeline

Source · CBE, NBB annual accounts

Year

Identity

Incorporation

Name

Registered office

Annual accounts

Filings7 filings

Mandates

SOCIETE FEDERALE DE PARTICIPATIONS ET D'INVESTISSEMENT

SPARAXIS

Newton Biocapital Partners

JCO Consulting

JUNOMATI

EJM Consulting

Graeme Fraser

GEMA

Elisabeth Svanberg

Franz Obermayr

Eric Paul Pâques

A Q INVEST

Show the 4 other mandates

2018201920202021202220232024202520262027202820292030

EPICS THERAPEUTICS

Rue Adrienne Bolland 47, 6041 Gosselies

Director

Managing director

Chairman of the board of directors

Director

Managing director

Director

CurrentPlanned, not yet servedEndedAccounts filedToday

Registered offices

Source · NBB annual accounts, CBE

Registered address	Period	Source
Rue Adrienne Bolland 47, 6041 GosseliesCurrent	accounts 2021 → 2025	Accounts 2025 · 2026-00186108

Company names

Source · NBB annual accounts, CBE

Name	Period	Source
EPICS THERAPEUTICSCurrent	accounts 2021 → 2025	Accounts 2025 · 2026-00186108

Events

2025
Annual accounts 2025-5,8 M €↓
2024
Annual accounts 2024-4,8 M €↑
2023
Annual accounts 2023-6,3 M €↓
2022
Annual accounts 2022-5,4 M €↓
2021
Annual accounts 2021-4,6 M €↓
2020
Annual accounts 2020-3,7 M €↓
2018
Annual accounts 2018-630,9 k €
20/02/2018
IncorporationPublic limited company

EPICS THERAPEUTICS

Overview

Identity

Financials

Valuation

Indicative valuation

Board of directors

Other companies at this address

Financials

Full financial information

Financial ratios

Annual accounts filings

Valuation

Indicative valuation

Directors & structure

Board of directors

Ownership and network

Publications

Belgian Official Gazette publications

Similar companies

Similar companies

Timeline

Timeline

Registered offices

Company names

Events